A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
BeOne Medicines
Incyte Corporation
AbbVie
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Vividion Therapeutics, Inc.
Seagen Inc.
Novartis
Hoffmann-La Roche
M.D. Anderson Cancer Center
EMD Serono
Pfizer
Pfizer
Abramson Cancer Center at Penn Medicine
AstraZeneca
Genentech, Inc.
University Hospital, Grenoble
Eli Lilly and Company
Peking University Cancer Hospital & Institute
GlaxoSmithKline
Pfizer
M.D. Anderson Cancer Center
Myeloid Therapeutics
AbbVie
University of Alabama at Birmingham
Toray Industries, Inc
Jiangsu Hansoh Pharmaceutical Co., Ltd.
City of Hope Medical Center
Shanghai Junshi Bioscience Co., Ltd.
Sapience Therapeutics
Exelixis
Inspirna, Inc.
IGM Biosciences, Inc.
Ohio State University Comprehensive Cancer Center
Second Affiliated Hospital, School of Medicine, Zhejiang University
Boehringer Ingelheim
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
MEI Pharma, Inc.
Pfizer
Taiho Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co. Ltd
Taiho Oncology, Inc.
Chugai Pharmaceutical
Ono Pharmaceutical Co. Ltd
Servier
Tesaro, Inc.
Shanghai Zhongshan Hospital
Lebanese University